Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Gyre Therapeutics (GYRE) over the last 9 years, with Q3 2025 value amounting to $18.7 million.

  • Gyre Therapeutics' Total Non-Current Liabilities rose 1712.7% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year increase of 1712.7%. This contributed to the annual value of $16.4 million for FY2024, which is 2015.31% down from last year.
  • As of Q3 2025, Gyre Therapeutics' Total Non-Current Liabilities stood at $18.7 million, which was up 1712.7% from $20.0 million recorded in Q2 2025.
  • Gyre Therapeutics' Total Non-Current Liabilities' 5-year high stood at $22.1 million during Q1 2025, with a 5-year trough of $1.8 million in Q3 2023.
  • Over the past 4 years, Gyre Therapeutics' median Total Non-Current Liabilities value was $16.7 million (recorded in 2024), while the average stood at $14.1 million.
  • Examining YoY changes over the last 5 years, Gyre Therapeutics' Total Non-Current Liabilities showed a top increase of 97982.65% in 2024 and a maximum decrease of 2015.31% in 2024.
  • Gyre Therapeutics' Total Non-Current Liabilities (Quarter) stood at $12.5 million in 2022, then skyrocketed by 64.31% to $20.5 million in 2023, then dropped by 20.15% to $16.4 million in 2024, then rose by 14.47% to $18.7 million in 2025.
  • Its last three reported values are $18.7 million in Q3 2025, $20.0 million for Q2 2025, and $22.1 million during Q1 2025.